Dogwood Therapeutics, Inc.
Halneuron
cancer-related pain and neuropathy
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for Halneuron in cancer-related pain and neuropathy are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Submitting our end of Phase 2 summary, manufacturing plans and Phase 3 clinical development plans to FDA towards the end of 2026, assuming favorable outcomes in our ongoing Halneuron Phase 2b program.”